|
Tafasitamab Clinical Trials
9 actively recruiting trials across 6 locations
▼ -2 trials since June 2026
Also known as: 1422527-84-1, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Dimer, Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Immunoglobulin +7 more
Pipeline
Phase 1: 1Phase 2: 6Phase 1/2: 2
Top Sponsors
- M.D. Anderson Cancer Center2
- University of Cologne1
- SWOG Cancer Research Network1
- OHSU Knight Cancer Institute1
- Masonic Cancer Center, University of Minnesota1
Indications
- Cancer8
- Systemic Sclerosis1
- Lupus Nephritis1
- Systemic Lupus Erythematosus1
- Autoimmune Disorders1
Other2 trials
Houston, Texas2 trials
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M D Anderson Cancer Center
Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
MD Anderson Cancer Center
Phase 1/2
Tucson, Arizona1 trial
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Banner University Medical Center - Tucson
Phase 2
Miami, Florida1 trial
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
University of Miami
Phase 1/2
Minneapolis, Minnesota1 trial
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center
Phase 2
Rochester, Minnesota1 trial
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Mayo Clinic in Rochester
Phase 2
Portland, Oregon1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.